NSPR DD
Updated
- Product: CGuard with MicroNET for Stroke Prevention
- Stroke is 2nd Leading Cause of Death Worldwide (WHO)
- Currently Sold in 39 Countries
- Expanding to Brazil, China, and Japan
- CE Mark -- FDA Approval Ongoing
- 14 USA, 33 World Patents
- 7 Successful Clinical Trials, 4 On-going
- Becoming the New Standard of Care
- Minimally Invasive Outpatient Procedure
- The MicroNET solves the problem of dislodging artery plaque during stent placement
- New CEO Marvin Solsman (January 2020) 30yr Exp
- GE Healthcare, Cordis, and Integra
- Focused on Commercialization and International Market Development
- Company Recapitalized for Growth Preparation
- 30% Growth in Q42019
- Stroke Management is BIG Business
- $34 Billion associated with Stroke Management in USA yearly
- Consolidation past few days
- Falling wedge - - possible reversal
looking for .5c break and retest of new support
PT1 .58c
PT2 .79c
PT3 .89c
PT4 1.04
stop .44c
- Stroke is 2nd Leading Cause of Death Worldwide (WHO)
- Currently Sold in 39 Countries
- Expanding to Brazil, China, and Japan
- CE Mark -- FDA Approval Ongoing
- 14 USA, 33 World Patents
- 7 Successful Clinical Trials, 4 On-going
- Becoming the New Standard of Care
- Minimally Invasive Outpatient Procedure
- The MicroNET solves the problem of dislodging artery plaque during stent placement
- New CEO Marvin Solsman (January 2020) 30yr Exp
- GE Healthcare, Cordis, and Integra
- Focused on Commercialization and International Market Development
- Company Recapitalized for Growth Preparation
- 30% Growth in Q42019
- Stroke Management is BIG Business
- $34 Billion associated with Stroke Management in USA yearly
- Consolidation past few days
- Falling wedge - - possible reversal
looking for .5c break and retest of new support
PT1 .58c
PT2 .79c
PT3 .89c
PT4 1.04
stop .44c
Note
Triple bottom just formed here. Will keep this on watch. Surprised this one hasn't taken off yet.Note
Holding strong in PM.Note
InspireMD Gains Registration Clearance of its CGuard™ Embolic Prevention System (EPS) in BrazilNote
Massive volume PM with PR should make this run at open.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.